Accord Healthcare Inc, a US-based generic pharmaceutical company, announced on Monday that it has added Teriflunomide to its range of oral medications.

The product, which is formulated as a film-coated tablet, is therapeutically equivalent to Sanofi Genzyme's Aubagio and is intended to treat relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease in adults.

Teriflunomide is offered in 14mg tablet and a seven mg tablet and is presently available for shipping. The FDA has approved the product for use as an immunomodulatory agent in subjects 18 and older to reduce the frequency and severity of disease flare-ups, called relapses, to prevent new symptoms or a worsening of old symptoms related to the disease's neurologic effect.

Accord Healthcare U.S. vice president of Sales Jim Brown, said: "We're proud to add Teriflunomide to our portfolio. This is an important oral therapy for the millions of patients living with relapsing MS. Generic medicine allows broad access to effective therapy, to help improve disease course and potentially slow progression of MS."